Shoji Yano
Internal Medicine · Los Angeles, CANPI 1538256979
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (42.4%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. Sanofi accounts for 70.6% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2019 at $7,827 and has fallen 96.4% since, to $280 in 2025. Among internal medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 116 payments — averaging $106.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$9K
- Biomarin Pharmaceutical Inc.$2K
- Sanofi-aventis U.S. LLC$1K
- Cycle Pharmaceuticals Inc$292
- PTC Therapeutics, Inc.$244
- Travere Therapeutics, Inc.$131
- plus $361 from 7 others
Across 42 payments — averaging $1791.51 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biomarin Pharmaceutical Inc.$70K
- Amgen$5K
- Sanofi US Services Inc.$525
What the payments were for
- Consulting fees$5,25042%
- Speaking & faculty fees$1,51012%
- Travel & lodging$1,39811%
- Food & beverage$3,69830%
- Education$5404%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 47 | $8,747 |
| Biomarin Pharmaceutical Inc. | 22 | $1,611 |
| Sanofi-aventis U.S. LLC | 1 | $1,010 |
| Cycle Pharmaceuticals Inc | 3 | $292 |
| PTC Therapeutics, Inc. | 4 | $244 |
| Travere Therapeutics, Inc. | 28 | $131 |
| Amgen | 1 | $116 |
| AstraZeneca | 2 | $60 |
| Ultragenyx Pharmaceutical Inc. | 2 | $60 |
| Rhythm Pharmaceuticals, Inc. | 2 | $50 |
| GSK | 2 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Amicus Therapeutics, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,397 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sapropterin Dihydrochloride | 71 | $306,695 |
| LevocarnitineLevocarnitine (With Sugar) | 42 | $9,399 |
| Levocarnitine | 24 | $4,492 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Los Angeles
- William HardyLos Angeles$704K
- Soha DolatabadiLos Angeles$458K
- Matthew HerrmannLos Angeles$384K
- Koppany VisnyeiLos Angeles$287K
- Jaime BetancourtLos Angeles$286K
- William KingLos Angeles$227K
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.